• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
MSB

MESOBLAST LIMITED - Corporate Spotlight

2.97% ! $1.80
Market Cap $2.293B  !

Mesoblast Limited is an Australia-based company, which is engaged in developing... Mesoblast Limited is an Australia-based company, which is engaged in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. It has leveraged its proprietary mesenchymal lineage cell therapy technology platform to establish a broad portfolio of late-stage product candidates. It is developing product candidates for distinct indications based on its remestemcel-L and rexlemestrocel-L allogeneic stromal cell technology platforms. Remestemcel-L is being developed for inflammatory diseases in children and adults including steroid refractory acute graft versus host disease, and biologic-resistant inflammatory bowel disease. Rexlemestrocel-L is being developed for advanced chronic heart failure (REVASCOR) and chronic low back pain (MPC-06-ID). Two products have been commercialized in Japan and Europe by the Company's licensees. It has established commercial partnerships in Europe and China for certain Phase III assets.More

No Corporate Spotlight currently available.

Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
Add to My Watchlist
(20min delay)
Last
$1.80
Change
-0.055(2.97%)
Mkt cap ! $2.293B
Open High Low Value Volume
$1.84 $1.86 $1.77 $7.241M 4.018M

Buyers (Bids)

No. Vol. Price($)
3 25472 $1.80
 

Sellers (Offers)

Price($) Vol. No.
$1.81 1500 1
View Market Depth
Last trade - 16.10pm 13/06/2025 (20 minute delay) ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.